Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991
Yousif Matloub(Roswell Park Comprehensive Cancer Center), Paul S. Gaynon(University of Southern California), Anne Angiolillo(Children's National), Catherine Cole(Maine Medical Center), Naomi Winick(The University of Texas Southwestern Medical Center), Patrick J. Buckley(Duke Medical Center), William L. Carroll(NYU Langone Health), Meenakshi Devidas(National Institutes of Health), Mei La(Arcadia), Blythe Thomson(Epizyme (United States)), Nyla A. Heerema(The Ohio State University), James B. Nachman(University of Chicago), Bruce Bostrom(Minnesota West Community & Technical College), Harland N. Sather(Children's Oncology Group), Stephen P. Hunger(Children's Hospital of Philadelphia)
Cited by 17
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|1.2k